Skip to main content

Advertisement

SpringerLink
Log in

Therapy-related myeloid neoplasms of recipient origin after allogeneic hematopoietic stem cell transplantation for acute leukemia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Some allogeneic stem cell transplantation (allo-SCT) recipients develop therapy-related myeloid neoplasms (t-MNs) of recipient origin with features including karyotypically abnormal hematopoiesis without cell dysplasia and myeloblast increase. However, due to their rarity their clinical course remains unclear. We report six cases of t-MN in patients with chromosomal abnormalities (CAs) after autologous recovery following allo-SCT for acute leukemia. CAs were first detected at a median interval of 422 (range 30–1941) days from allo-SCT. The fraction of CA-bearing cells of recipient origin increased with time, and cytogenetic relapse of underlying disease was not observed. Continuous emergence of identical autologous CAs was observed in one patient who did not receive total body irradiation (TBI). The other five patients received TBI, and complex karyotypes with the appearance of different types of CAs were the most dominant feature. Despite the persistence of complex abnormalities in the irradiated patients, no patient developed therapy-related acute myeloid leukemia (t-AML). TBI appears to be the major cause of t-MN of recipient origin with different types of CAs. Although t-MNs in patients receiving TBI do not initially seem to evolve to overt t-AML, they were associated with higher risk of underlying disease and greater oncogenic potential of irradiation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Brunstein CG, Hirsch BA, JS Miller, McGlennen RC, Verfaillie CM, Weisdorf DJ, et al. Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse. Bone Marrow Transplant. 2000; 26:1173–7.

  2. Kato M, Nakasone H, Nakano N, Fuji S, Shinohara A, Ogata M, et al. Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transp. 2020;55:1023–8.

    Article  CAS  Google Scholar 

  3. Lin YW, Hamahata K, Watanabe K, Adachi S, Akiyama Y, Nakahata T, et al. Repetitious appearance and disappearance of different kinds of clonal cytogenomic abnormalities after allogeneic bone marrow transplantation. Int J Hematol. 2001;74:86–9.

    Article  CAS  PubMed  Google Scholar 

  4. Au WY, Lie AK, Ma SK, Leung YH, Siu LL, Kwong YL. Therapy-related myelodysplastic syndrome of recipient origin after allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Br J Haematol. 2001;112:424–6.

    Article  CAS  PubMed  Google Scholar 

  5. Yoshihara T, Hibi S, Yamane Y, Morimoto A, Hashida T, Iwami H, et al. Numerous nonclonal chromosomal aberrations arising in residual recipient hematopoietic cells following allogeneic bone marrow transplantation. Bone Marrow Transp. 2005;35:587–9.

    Article  CAS  Google Scholar 

  6. Yamasaki S, Suzuki R, Hatano K, Fukushima K, Iida H, Suzumiya J, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. Bone Marrow Transp. 2017;52:969–76.

    Article  CAS  Google Scholar 

  7. Kuno M, Yamasaki S, Fujii N, Ishida Y, Fukuda T, Inamoto Y, et al. Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation. Am J Hematol. 2022;97:185–93.

    Article  CAS  PubMed  Google Scholar 

  8. Thiede C, Bornhauser M, Ehuinger G. Strategies and clinical implications of chimerism diagnosis after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2004;112:16–23.

    Article  PubMed  Google Scholar 

  9. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Wilson RK, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552–5.

    Article  CAS  PubMed  Google Scholar 

  10. Heuser M. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematol Am Soc Hematol Educ Program. 2016;2016:24–32.

    Article  Google Scholar 

  11. Perot C, van den Akker J, Laporte JP, Douay L, Lopez M, Gorin NC, et al. Multiple chromosome abnormalities in patients with acute leukemia after autologous bone marrow transplantation using total body irradiation and marrow purged with mafosfamide. Leukemia. 1993;7:509–15.

    CAS  PubMed  Google Scholar 

  12. Nagayama H, Misawa K, Tanaka H, Ooi J, Iseki T, Asano S, et al. Transient hematopoietic stem cell rescue using umbilical cord blood for a lethally irradiated nuclear accident victim. Bone Marrow Transpl. 2002;29:197–204.

    Article  CAS  Google Scholar 

  13. Baranov A, Gale RP, Guskova A, Piatkin E, Selidovkin G, Muravyova L, et al. Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med. 1989;321:205–12.

    Article  CAS  PubMed  Google Scholar 

  14. Taguchi M, Mishima H, Shiozawa Y, Hayashida C, Kinoshita A, Nannya Y, et al. Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Haematologica. 2020;105:358–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Horai M, Satoh S, Matsuo M, Iwanaga M, Horio K, Miyazaki Y, et al. Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Br J Haematol. 2018;180:381–90.

    Article  CAS  PubMed  Google Scholar 

  16. Yabe M, Morimoto T, Shimizu T, Koike T, Takakura H, Yabe H, et al. Therapy-related myelodysplastic syndrome of recipient origin in a juvenile myelomonocytic leukemia patient 17 years after allogeneic BMT. Bone Marrow Transplant. 2011;46:1023–5.

    Article  CAS  PubMed  Google Scholar 

  17. Turcotte LM, Whitton JA, Friedman DL, Hammond S, Armstrong GT, Leisenring W, et al. Risk of subsequent neoplasms during the fifth and sixth decades of life in the childhood cancer survivor study cohort. J Clin Oncol. 2015;33:3568–75.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Saso R, Zomas A, Hamblin M, Dunlop L, Swansbury GJ, Mehta J, et al. Sequential development of myelodysplasia and acute myeloid leukemia but with no karyotypic evolution after autografting in a patient with Philadelphia positive acute lymphoblastic leukemia. Leuk Lymphoma. 1997;26:625–8.

    Article  CAS  PubMed  Google Scholar 

  19. Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Felice MS, et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol. 2012;87:890–7.

    Article  PubMed  Google Scholar 

  20. Dorantes-Acosta E, Pelayo R. Lineage switching in acute leukemias: a consequence of stem cell plasticity? Bone Marrow Res. 2012;2012: 406796.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hu T, Murdaugh R, Nakada D. Transcriptional and microenvironmental regulation of lineage ambiguity in leukemia. Front Oncol. 2017;7:268.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Tomonaga M, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29:428–34.

    Article  PubMed  Google Scholar 

  23. Saito Y, Kobayashi J, Kanemaki MT, Komatsu K. RIF1 controls replication initiation and homologous recombination repair in a radiation dose-dependent manner. J Cell Sci. 2020; 133: jcs240036.

  24. Roos-Weil D, Nguyen S, Uzunov M, Bories D, Chapiro E, Nguyen-Khac F, et al. Therapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusions. Bone Marrow Transp. 2010;45:1471–3.

    Article  CAS  Google Scholar 

  25. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Kobbe G, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27:1229–35.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leukemia Research Center, Saiseikai Maebashi Hospital, Kamishinden-machi, 564-1, Maebashi, Gunma, 371-0821, Japan

    Takumi Hoshino, Nahoko Hatsumi, Hiromasa Iino & Satoru Takada

Authors
  1. Takumi Hoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nahoko Hatsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiromasa Iino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoru Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takumi Hoshino.

Ethics declarations

Conflict of interest

The authors declare that they have no confict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoshino, T., Hatsumi, N., Iino, H. et al. Therapy-related myeloid neoplasms of recipient origin after allogeneic hematopoietic stem cell transplantation for acute leukemia. Int J Hematol 116, 902–910 (2022). https://doi.org/10.1007/s12185-022-03442-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03442-5

Keywords

Search

Navigation